Journal Article DZNE-2020-05214

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2016
Wiley-Blackwell Hoboken, NJ

Annals of neurology 80(5), 674-685 () [10.1002/ana.24781]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: We hypothesized that specific mutations in the β-glucocerebrosidase gene (GBA) causing neuropathic Gaucher's disease (GD) in homozygotes lead to aggressive cognitive decline in heterozygous Parkinson's disease (PD) patients, whereas non-neuropathic GD mutations confer intermediate progression rates.A total of 2,304 patients with PD and 20,868 longitudinal visits for up to 12.8 years (median, 4.1) from seven cohorts were analyzed. Differential effects of four types of genetic variation in GBA on longitudinal cognitive decline were evaluated using mixed random and fixed effects and Cox proportional hazards models.Overall, 10.3% of patients with PD and GBA sequencing carried a mutation. Carriers of neuropathic GD mutations (1.4% of patients) had hazard ratios (HRs) for global cognitive impairment of 3.17 (95% confidence interval [CI], 1.60-6.25) and a hastened decline in Mini-Mental State Exam scores compared to noncarriers (p = 0.0009). Carriers of complex GBA alleles (0.7%) had an HR of 3.22 (95% CI, 1.18-8.73; p = 0.022). By contrast, the common, non-neuropathic N370S mutation (1.5% of patients; HR, 1.96; 95% CI, 0.92-4.18) or nonpathogenic risk variants (6.6% of patients; HR, 1.36; 95% CI, 0.89-2.05) did not reach significance.Mutations in the GBA gene pathogenic for neuropathic GD and complex alleles shift longitudinal cognitive decline in PD into 'high gear.' These findings suggest a relationship between specific types of GBA mutations and aggressive cognitive decline and have direct implications for improving the design of clinical trials. Ann Neurol 2016;80:674-685.

Keyword(s): Aged (MeSH) ; Aged, 80 and over (MeSH) ; Cognitive Dysfunction: etiology (MeSH) ; Cognitive Dysfunction: genetics (MeSH) ; Disease Progression (MeSH) ; Female (MeSH) ; Gaucher Disease: complications (MeSH) ; Gaucher Disease: genetics (MeSH) ; Glucosylceramidase: genetics (MeSH) ; Humans (MeSH) ; Longitudinal Studies (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Parkinson Disease: complications (MeSH) ; Parkinson Disease: genetics (MeSH) ; Glucosylceramidase

Classification:

Contributing Institute(s):
  1. Genome Biology of Neurodegenerative Diseases (AG Heutink 1)
Research Program(s):
  1. 345 - Population Studies and Genetics (POF3-345) (POF3-345)

Appears in the scientific report 2016
Database coverage:
Medline ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Heutink
Public records
Publications Database

 Record created 2020-02-18, last modified 2024-03-21


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)